Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or General Tonic-clonic Seizures

Trial Profile

A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or General Tonic-clonic Seizures

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lacosamide (Primary) ; Carbamazepine
  • Indications Partial epilepsies; Tonic-clonic epilepsy
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors UCB
  • Most Recent Events

    • 01 Nov 2023 Results of Exploratory post hoc analysis evaluating the efficacy and tolerability of lacosamide (LCM) versus controlled release carbamazepine (CBZ-CR) monotherapy in adults with newly diagnosed , published in the Seizure: European Journal of Epilepsy
    • 17 Nov 2020 Results (n=271) of post-hoc analysis assessing serologic data from a randomized monotherapy trial comparing the controlled-release formulation of CBZ with LCM for the treatment of new-onset focal epilepsy, published in the Epilepsia.
    • 12 Nov 2019 Results of post hoc analyses of pooled long term safety and efficacy data from (NCT01465997 and NCT01243177) published in the Epilepsia published in the Epilepsia
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top